Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.

Piening, Alexander; Ebert, Emily; Khojandi, Niloufar; Alspach, Elise; Teague, Ryan M

Piening, Alexander; Ebert, Emily; Khojandi, Niloufar; Alspach, Elise; Teague, Ryan M.

Afiliação

Piening A; Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis MO, United States.
Ebert E; Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis MO, United States.
Khojandi N; Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis MO, United States.
Alspach E; Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis MO, United States.
Teague RM; Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis MO, United States.

Front Immunol ; 13: 1022732, 2022.

Article em En | MEDLINE | ID: mdl-36582225

Assuntos

COVID-19; Neoplasias; Humanos; SARS-CoV-2; Inibidores de Checkpoint Imunológico/efeitos adversos; COVID-19/terapia; Vacinas contra COVID-19/efeitos adversos; Estudos Prospectivos; Imunoterapia/efeitos adversos; Neoplasias/terapia; Anticorpos Antivirais; Imunoglobulina G; Imunidade

Palavras-chave

COVID - 19; cancer; immune checkpoint blockade (ICB); immunotherapy; vaccination

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: COVID-19 / Neoplasias Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google